Kamada will seek FDA approval for AAT for the treatment of congenital emphysema next year.
Kamada Ltd. (TASE: KMDA) today announced that it has completed the Phase III clinical trial of its Alpha-1 Antitrypsin (AAT) protein for the treatment of congenital emphysema. The US Food and Drug Administration (FDA) approved trial was conducted in the US. The company plans to file a biologic license application (BLA) for the drug with the FDA next year.
Kamada fell 8% today to NIS 16.57, giving a market cap of NIS 282 million.
The company stated, "The trial results demonstrated an excellent safety and effectiveness profile of the drug (the level of the AAT protein in the blood)."
AAT is currently undergoing a Phase II clinical trial for the treatment of cystic fibrosis.
Published by Globes [online], Israel business news - www.globes-online.com - on October 26, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008